Global Physician Survey on Stents, Stent-Grafts and Vulnerable Plaque Treatment 2011

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

Global Physician Survey on Stents, Stent-Grafts and Vulnerable
Plaque Treatment 2011
Published on January 2011

Report Summary

This report details the responses of a comprehensive survey conducted of interventional cardiologists, interventional radiologists and
cardiac surgeons on product preferences, placement techniques and trends in the use of drug eluting and bare metal stents,
bifurcated stents, bioabsorbable stents, stent grafts, vulnerable plaque diagnosis and treatment and endovascular imaging
technologies. The Global Physician Survey on Stents, Stent-Grafts and Endovascular Imaging includes:

- The United States
- Europe
- Asia-Pacific
- Latin America
- Middle East
- Africa

This report covers:

- Number and Type of Stents Placed
- Type of Endovascular Imaging Used
- Bifurcated Stents and Their Use
- Most Important Benefit When Using Bifurcated Stents
- Preferred Bifurcated Stent Alternative
- Bioabsorbable Stents and Their Use
- Most Important Benefit When Using Bioabsorbable Stents
- Most Important Bioabsorable Stent Drawback
- Most Important Drug-Eluting Stent Concern
- Most Effective Drug-Eluting Stent Drug for Combating Restenosis
- Stent-Graft Brand Preference
- Most Important Construction Feature for Stent-Grafts
- Most Important Design Feature for Next Generation Stent-Grafts
- The Use of Thoracic Aortic Aneurysm (TAA) Stent-Grafts
- Concerns about the Use of TAA Stent-Grafts

Table of Content

TABLE OF CONTENTS

Global Physician Survey on Stents, Stent-Grafts and Vulnerable Plaque Treatment 2011 (From Slideshare) Page 1/16


EXECUTIVE SUMMARY. 1
1.1 SURVEY OVERVIEW 1
1.2 CORONARY AND PERIPHERAL STENTS . 2
1.3 ENDOVASCULAR IMAGING TECHNOLOGY 3
1.4 BIFURCATED STENT BENEFITS AND DRAWBACKS . 3
1.5 ALTERNATIVES TO BIFURCATED STENTS . 4
1.6 BIOABSORBABLE STENT BENEFITS AND DRAWBACKS. 5
1.7 DRUG-ELUTING STENTS . 5
1.8 IMPORTANT STENT-GRAFT CONSTRUCTION FEATURES. 6
1.9 STENT-GRAFT BRAND PREFERENCE. 6
1.10 THORACIC ABDOMINAL ANEURYSM STENT-GRAFTS 6
1.11 VULNERABLE PLAQUE SCREENING 7
1.12 VULNERABLE PLAQUE TREATMENT. 8
1.13 LIST OF COUNTRIES AND TOPICS 9
SURVEY HIGHLIGHTS 2
2.1 RESPONDENT CHARACTERISTICS . 2
2.2 RESPONSE SUMMARY . 4
RESEARCH METHODOLOGY. 5
3.1 RESEARCH SCOPE . 5
GLOBAL STENTS, STENT-GRAFTS AND VULNERABLE PLAQUE 6
4.1 INTRODUCTION . 6
4.1.1 Bioabsorbable Stents 6
4.1.2 Bifurcated Stents . 7
4.1.3 Stent-Grafts. 8
4.1.4 Vulnerable Plaque 9
4.2 GLOBAL OVERVIEW FOR STENTS, STENT-GRAFTS AND VULNERABLE PLAQUE 11
4.2.1 Geographical Distribution 11
4.2.2 Respondent Specialty 12
4.2.3 Number and Type of Stents Placed . 14
4.2.4 Type of Endovascular Imaging Used 17
4.2.5 Bifurcated Stents and Their Use . 21
4.2.6 Most Important Benefit of Bifurcated Stents. 25
4.2.7 Most Important Bifurcated Stent Drawback . 28
4.2.8 Preferred Bifurcated Stent Alternatives 31
4.2.9 Bioabsorbable Stents and Their Use. 37
4.2.10 Most Important Bioabsorbable Stent Benefit 41
4.2.11 Most Important Bioabsorbable Stent Drawback 45
4.2.12 Most Important Drug-Eluting Stent Concern . 48
4.2.13 Most Effective Drug-Eluting Stent Drug for Combating Restenosis 51
4.2.14 Stent-Graft Brand Preference . 56
4.2.15 Most Important Construction Feature for Stent-Grafts 62
4.2.16 Most Important Design Feature for Next-Generation Stent-Grafts 65
4.2.17 The Use of Thoracic Aortic Aneurysm (TAA) Stent-Grafts. 68
4.2.18 Concerns about the Use of TAA Stent-Grafts . 70
4.2.19 Most Promising Vulnerable Plaque Screening Technology . 73
4.2.20 Most Promising Vulnerable Plaque Treatment Technology. 77
U.S. STENTS, STENT-GRAFTS AND VULNERABLE PLAQUE . 80
5.1 GEOGRAPHICAL DISTRIBUTION 80



5.2 RESPONDENT SPECIALTY 81
5.3 NUMBER AND TYPE OF STENTS PLACED 82
5.4 TYPE OF ENDOVASCULAR IMAGING USED . 87
5.5 BIFURCATED STENTS AND THEIR USE 91
5.6MOST IMPORTANT BENEFIT WHEN USING BIFURCATED STENTS 92
5.7 DRAWBACKS TO THE USE OF BIFURCATED STENTS. 94
5.8 PREFERRED BIFURCATED STENT ALTERNATIVES 97
5.8.1 Preferred Bifurcated Stent Alternatives by Specialty . 99
5.9 BIOABSORBABLE STENTS AND THEIR USE . 102
5.10MOST IMPORTANT BENEFIT WHEN USING BIOABSORBABLE STENTS . 103
5.11MOST IMPORTANT BIOABSORBABLE STENT DRAWBACK 105
5.12MOST IMPORTANT DRUG-ELUTING STENT CONCERN 107
5.13MOST EFFECTIVE DRUG-ELUTING STENT DRUG FOR COMBATING RESTENOSIS. 109
5.13.1 Most Effective Drug-Eluting Stent Drug for Combating Restenosis by
Specialty 111
5.14 PREFERRED BRAND OF STENT-GRAFT 114
5.15MOST IMPORTANT CONSTRUCTION FEATURE FOR STENT-GRAFTS . 116
5.16MOST IMPORTANT DESIGN FEATURE FOR NEXT-GENERATION STENT-GRAFTS. 118
5.17 THE USE OF THORACIC AORTIC ANEURYSM STENT-GRAFTS 120
5.18 CONCERNS ABOUT THE USE OF TAA STENT-GRAFTS 122
5.19MOST PROMISING VULNERABLE PLAQUE SCREENING TECHNOLOGY. 124
5.19.1 Most Promising Vulnerable Plaque Screening Technology by Specialty. 127
5.20MOST PROMISING VULNERABLE PLAQUE TREATMENT TECHNOLOGY 131
5.20.1 Most Promising Vulnerable Plaque Treatment Technology by Specialty 133
EUROPEAN STENTS, STENT-GRAFTS AND VULNERABLE PLAQUE 136
6.8.1 Preferred Bifurcated Stent Alternatives by Specialty . 153
6.13.1 Most Effective Drug-Eluting Stent Drug for Combating Restenosis by
Specialty 164
6.16MOST IMPORTANT DESIGN FEATURE FOR NEXT-GENERATION STENT-GRAFTS . 171
6.17 THE USE OF THORACIC AORTIC ANEURYSM (TAA) STENT-GRAFTS 173
6.19.1 Most Promising Vulnerable Plaque Screening Technology by Specialty. 179



LATIN AMERICAN STENTS, STENT-GRAFTS AND VULNERABLE PLAQUE 184
7.4.1 Imaging Technology Preference by Country 189
ASIA-PACIFIC STENTS, STENT-GRAFTS AND VULNERABLE PLAQUE. 222
MIDDLE EASTERN AND AFRICAN STENTS, STENT-GRAFTS AND
VULNERABLE PLAQUE 262



ABBREVIATIONS 302
APPENDIX 303
11.1 GEOGRAPHIC DISTRIBUTION OF RESPONSES 303
11.2 TECHNIQUES FOR STENTING BIFURCATED LESIONS 306
11.3 SAMPLE SURVEY. 307

LIST OF FIGURES

EXECUTIVE SUMMARY 1
SURVEY HIGHLIGHTS 2
Figure 2-1: Respondent Characteristics, Stents, Stent-Grafts and Vulnerable
Plaque, 2010 2
Figure 2-2: Respondent Characteristics, Stents, Stent-Grafts and Vulnerable
Plaque, 2010 3
RESEARCH METHODOLOGY 5
Figure 4-1: Geographical Distribution, Global Respondents, 2010 . 11
Figure 4-2: Respondent Specialty, Global Responses, 2010 12
Figure 4-3: Coronary and Peripheral Stents Placed per Month, Global Responses,
2010 15
Figure 4-4: Imaging Technology Preferences, Percentage of Use for
Respondents, Global Responses, 2010 18
Figure 4-5: Imaging Technology Preferences for Endovascular Procedures,
Global Responses, 2010 . 19
Figure 4-6: Bifurcated Stents and Their Use, Global Responses, 2010 21
Figure 4-7: Most Important Bifurcated Stent Benefit, Global Responses, 2010 . 26
Figure 4-8: Most Important Bifurcated Stent Drawback, Global Responses,
2010 29



Figure 4-9: Preferred Bifurcated Stent Alternatives, Global Responses, 2010
(Part 1 of 2) . 32
Figure 4-10: Preferred Bifurcated Stent Alternatives, Global Responses, 2010
(Part 2 of 2) . 33
Figure 4-11: Bioabsorbable Stents and Their Use, Global Responses, 2010. 37
Figure 4-12: Most Important Bioabsorbable Stent Benefit, Global Responses,
2010 (Part 1 of 2) 42
Figure 4-13: Most Important Bioabsorbable Stent Benefit, Global Responses,
2010 (Part 2 of 2) 43
Figure 4-14: Most Important Bioabsorbable Stent Drawback, Global Responses,
2010 46
Figure 4-15: Most Important Drug-Eluting Stent Concern, Global Responses,
2010 49
Figure 4-16: Most Effective Drug-Eluting Stent Drug for Combating Restenosis,
Figure 4-17: Stent-Graft Brand Preference, Global Responses, 2010
(Part 1 of 2) . 57
Figure 4-18: Stent-Graft Brand Preference, Global Responses, 2010
(Part 2 of 2) . 58
Figure 4-19: Most Important Construction Feature for Stent-Grafts, Global
Responses, 2010 (Part 1 of 2). 63
Figure 4-20: Most Important Construction Feature for Stent-Grafts, Global
Figure 4-21: Most Important Design Feature for Next-Generation Stent-Grafts,
Figure 4-22: The Use of Thoracic Aortic Aneurysm (TAA) Stent-Grafts, Global
Responses, 2010 68
Figure 4-23: Concerns about the Use of TAA Stent-Grafts, Global Responses,
2010 (Part 1 of 2) 71
Figure 4-24: Concerns about the Use of TAA Stent-Grafts, Global Responses,
2010 (Part 2 of 2) 71
Figure 4-25: Most Promising Vulnerable Plaque Screening Technology, Global
Figure 4-26: Most Promising Vulnerable Plaque Screening Technology, Global
Figure 4-27: Most Promising Vulnerable Plaque Treatment Technology, Global
Responses, 2010 78
U.S. STENTS, STENT-GRAFTS AND VULNERABLE PLAQUE. 80
Figure 5-1: Distribution of Survey Respondents by Geographic Region, U.S.
Responses, 2010 80
Figure 5-2: Distribution of Survey Respondents by Specialty, U.S. Responses,
2010 81
Figure 5-3: Number and Type of Stents Placed, U.S. Responses, 2010. 83
Figure 5-4: Type of Medical Imaging Used for Endovascular Procedures, U.S.
Responses, 2010 88
Figure 5-5: Type of Medical Imaging Used for Endovascular Procedures by
Specialty, U.S. Responses, 2010 89
Figure 5-6: Bifurcated Stents and Their Use, U.S. Responses, 2010 91



Figure 5-7: Most Important Benefit When Using Bifurcated Stents, U.S.
Responses, 2010 92
Figure 5-8: Drawbacks to the Use of Bifurcated Stents, U.S. Responses, 2010 95
Figure 5-9: Preferred Bifurcated Stent Alternatives, U.S. Responses, 2010 . 97
Figure 5-10: Preferred Bifurcated Stent Alternatives by Specialty, U.S.
Responses, 2010 100
Figure 5-11: Bioabsorbable Stents and Their Use, U.S. Responses, 2010 102
Figure 5-12: Most Important Benefit When Using Bioabsorbable Stents, U.S.
Responses, 2010 103
Figure 5-13: Most Important Bioabsorbable Stent Drawback, U.S. Responses,
2010 105
Figure 5-14: Most Important Drug-Eluting Stent Concern, U.S. Responses,
2010 107
U.S. Responses, 2010. 109
Figure 5-16: Most Effective Drug-Eluting Stent Drug for Combating Restenosis
by Specialty, U.S. Responses, 2010 112
Figure 5-17: Preferred Brand of Stent-Graft, U.S. Responses, 2010 115
Figure 5-18: Most Important Construction Feature for Stent-Grafts, U.S.
Responses, 2010 117
Figure 5-20: Use of Thoracic Aortic Aneurysm (TAA) Stent-Grafts, U.S.
Responses, 2010 120
Figure 5-21: Concerns about the Use of TAA Stent-Grafts, U.S. Responses,
2010 122
Figure 5-22: Most Promising Vulnerable Plaque Screening Technology, U.S.
Responses, 2010 125
Figure 5-23: Most Promising Vulnerable Plaque Screening Technology by
Specialty, U.S. Responses, 2010 (Part 1 of 2) 128
Specialty, U.S. Responses, 2010 (Part 2 of 2) 129
Figure 5-25: Most Promising Vulnerable Plaque Treatment Technology, U.S.
Responses, 2010 132
Figure 5-26: Most Promising Vulnerable Plaque Treatment Technology by
Figure 6-1: Distribution of Survey Respondents by Geographic Region,
European Responses, 2010 . 136
Figure 6-2: Distribution of Survey Respondents by Specialty, European
Responses, 2010 137
Figure 6-3: Number and Type of Stents Placed Per Month, European Responses,
2010 139
Figure 6-4: Type of Medical Imaging Used for Endovascular Procedures,
Specialty, European Responses, 2010 . 144
Figure 6-6: Bifurcated Stents and Their Use, European Responses, 2010 146



Figure 6-7: Most Important Benefit When Using Bifurcated Stents, European
Responses, 2010 147
Figure 6-8: Drawbacks to the Use of Bifurcated Stents, European Responses,
2010 150
Figure 6-9: Preferred Bifurcated Stent Alternatives, European Responses,
2010 151
Figure 6-10: Preferred Bifurcated Stent Alternatives by Specialty, European
Responses, 2010 153
Figure 6-11: Bioabsorbable Stents and Their Use, European Responses, 2010. 155
Figure 6-12: Most Important Benefit When Using Bioabsorbable Stents,
Figure 6-13: Most Important Bioabsorbable Stent Drawback, European
Responses, 2010 158
Figure 6-14: Most Important Drug-Eluting Stent Concern, European Responses,
2010 160
Figure 6-16: Most Effective Drug-Eluting Stent Drug for Combating Restenosis
by Specialty, European Responses, 2010 165
Figure 6-17: Preferred Brand of Stent-Graft, European Responses, 2010 168
Figure 6-18: Most Important Construction Feature for Stent-Grafts, European
Responses, 2010 170
Figure 6-20: Use of Thoracic Aortic Aneurysm (TAA) Stent-Grafts, European
Responses, 2010 173
Figure 6-21: Concerns about the Use of TAA Stent-Grafts, European Responses,
2010 175
Figure 6-22: Most Promising Vulnerable Plaque Screening Technology,
Specialty, European Responses, 2010 . 180
Figure 6-24: Most Promising Vulnerable Plaque Treatment Technology,
LATIN AMERICAN STENTS, STENT-GRAFTS AND VULNERABLE
PLAQUE . 184
Latin American Responses, 2010 184
Figure 7-2: Number and Type of Stents Placed per Month, Latin American
Responses, 2010 185
Country, Latin American Responses, 2010 . 190
Figure 7-5: Bifurcated Stents and Their Use, Latin American Responses,
2010 193
Figure 7-6: Most Important Benefit When Using Bifurcated Stents,



Figure 7-7: Drawbacks to the Use of Bifurcated Stents, Latin American
Responses, 2010 196
Figure 7-8: Preferred Bifurcated Stent Alternatives, Latin American Responses,
2010 198
Figure 7-9: Bioabsorbable Stents and Their Use, Latin American Responses,
2010 200
Figure 7-11: Most Important Bioabsorbable Stent Drawback, Latin American
Responses, 2010 203
Figure 7-12: Most Important Drug-Eluting Stent Concern, Latin American
Responses, 2010 205
Figure 7-14: Preferred Brand of Stent-Graft, Latin American Responses, 2010 . 209
Figure 7-15: Most Important Construction Feature for Stent-Grafts,
Figure 7-17: Use of Thoracic Aortic Aneurysm (TAA) Stent-Grafts,
Figure 7-18: Concerns about the Use of TAA Stent-Grafts, Latin American
Responses, 2010 216
ASIA-PACIFIC STENTS, STENT-GRAFTS AND VULNERABLE PLAQUE 222
Asia-Pacific Responses, 2010. 222
Figure 8-2: Preferred Imaging Technology for DVT Diagnosis, Asia-Pacific
Responses, 2010 223
Figure 8-3: Number and Type of Stents Placed per Month, Asia-Pacific
Responses, 2010 224
Country, Asia-Pacific Responses, 2010 230
Figure 8-6: Bifurcated Stents and Their Use, Asia-Pacific Responses, 2010 231
Figure 8-7: Most Important Benefit When Using Bifurcated Stents, Asia-Pacific
Responses, 2010 232
Figure 8-8: Drawbacks to the Use of Bifurcated Stents, Asia-Pacific Responses,
2010 235
Figure 8-9: Preferred Bifurcated Stent Alternatives, Asia-Pacific Responses,
2010 237
Figure 8-10: Bioabsorbable Stents and Their Use, Asia-Pacific Responses,
2010 239



Figure 8-12: Most Important Bioabsorbable Stent Drawback, Asia-Pacific
Responses, 2010 242
Figure 8-13: Most Important Drug-Eluting Stent Concern, Asia-Pacific
Responses, 2010 244
Figure 8-15: Preferred Brand of Stent-Graft, Asia-Pacific Responses, 2010 248
Figure 8-16: Most Important Construction Feature for Stent-Grafts, Asia-Pacific
Responses, 2010 251
Figure 8-19: Concerns about the Use of TAA Stent-Grafts, Asia-Pacific
Responses, 2010 255
MIDDLE EASTERN AND AFRICAN STENTS, STENT-GRAFTS AND
VULNERABLE PLAQUE 262
Middle Eastern and African Responses, 2010 . 262
Figure 9-2: Number and Type of Stents Placed per Month, Middle Eastern and
African Responses, 2010 263
Country, Middle Eastern and African Responses, 2010 . 270
Figure 9-5: Bifurcated Stents and Their Use, Middle Eastern and African
Responses, 2010 270
Figure 9-6: Most Important Benefit When Using Bifurcated Stents,
Figure 9-7: Drawbacks to the Use of Bifurcated Stents, Middle Eastern and
Figure 9-8: Preferred Bifurcated Stent Alternatives, Middle Eastern and African
Responses, 2010 276
Figure 9-9: Bioabsorbable Stents and Their Use, Middle Eastern and African
Responses, 2010 278
Figure 9-11: Most Important Bioabsorbable Stent Drawback, Middle Eastern and
Figure 9-12: Most Important Drug-Eluting Stent Concern, Middle Eastern and



Figure 9-14: Preferred Brand of Stent-Graft, Middle Eastern and African
Responses, 2010 288
Figure 9-15: Most Important Construction Feature for Stent-Grafts,
Figure 9-18: Concerns about the Use of TAA Stent-Grafts, Middle Eastern and
ABBREVIATIONS 302
APPENDIX 303
Figure 11-1: Geographic Distribution of Responses, U.S., 2010 . 303
Figure 11-2: Geographic Distribution of Responses, European Region, 2010 304
Figure 11-3: Geographic Distribution of Responses, Latin American Region,
2010 304
Figure 11-4: Geographic Distribution of Responses, Asia-Pacific Region,
2010 305
Figure 11-5: Geographic Distribution of Responses, Middle Eastern and African
Region, 2010 . 305

LIST OF CHARTS

EXECUTIVE SUMMARY 1
Chart 1-1: Respondent Location by Geographic Region, Global Responses,
Stents, Stent-Grafts and Vulnerable Plaque, 2010 . 1
Chart 1-2: Average Number of Stents Placed per Month by Respondents, Global
Responses, Stents, Stent-Grafts and Vulnerable Plaque, 2010 . 2
Chart 1-3: Bifurcated Stent Alternatives, Global Responses, Stents, Stent-Grafts
and Vulnerable Plaque, 2010 4
Chart 1-4: Vulnerable Plaque Screening Technology, Global Responses, Stents,
Stent-Grafts and Vulnerable Plaque, 2010 7
Chart 1-5: Most Promising Vulnerable Plaque Treatment, U.S. Respondents,
Stents, Stent-Grafts and Vulnerable Plaque, 2010 . 8
SURVEY HIGHLIGHTS 2
RESEARCH METHODOLOGY 5
Chart 4-1: Respondent Specialty, Global Responses, 2010 13
Chart 4-2: Average Stents Placed per Respondent, Global Responses, 2010 16
Chart 4-3: Imaging Technology Preferences, Percentage of Total, Global
Responses, 2010 20
Chart 4-4: Bifurcated Stents and Their Use, U.S. Responses, 2010 . 22
Chart 4-5: Bifurcated Stents and Their Use, European Responses, 2010 22



Chart 4-6: Bifurcated Stents and Their Use, Latin American Responses, 2010 23
Chart 4-7: Bifurcated Stents and Their Use, Asia-Pacific Responses, 2010 . 23
Chart 4-8: Bifurcated Stents and Their Use, Middle Eastern and African
Responses, 2010 24
Chart 4-9: Most Important Bifurcated Stent Benefit, Global Responses, 2010 . 27
Chart 4-10: Most Important Bifurcated Stent Drawback, Global Responses,
2010 30
Chart 4-11: Preferred Bifurcated Stent Alternatives, U.S. Responses, 2010. 34
Chart 4-12: Preferred Bifurcated Stent Alternatives, European Responses, 2010 . 34
Chart 4-13: Preferred Bifurcated Stent Alternatives, Latin American Responses,
2010 35
Chart 4-14: Preferred Bifurcated Stent Alternatives, Asia-Pacific Responses,
2010 35
Chart 4-15: Preferred Bifurcated Stent Alternatives, Middle Eastern and African
Responses, 2010 36
Chart 4-16: Bioabsorbable Stents and Their Use, U.S. Responses, 2010 38
Chart 4-17: Bioabsorbable Stents and Their Use, European Responses, 2010 38
Chart 4-18: Bioabsorbable Stents and Their Use, Latin American Responses,
2010 39
Chart 4-19: Bioabsorbable Stents and Their Use, Asia-Pacific Responses, 2010 39
Chart 4-20: Bioabsorbable Stents and Their Use, Middle Eastern and African
Responses, 2010 40
Chart 4-21: Most Important Bioabsorbable Stent Benefit, Global Responses,
2010 44
Chart 4-22: Most Important Bioabsorbable Stent Drawback, Global Responses,
2010 47
Chart 4-23: Most Important Drug-Eluting Stent Concern, Global Responses,
2010 50
Chart 4-24: Most Effective Drug-Eluting Stent Drug for Combating Restenosis,



Chart 4-34: Most Important Construction Feature for Stent-Grafts, Global
Responses, 2010 64
Chart 4-35: Most Important Design Feature for Next-Generation Stent-Grafts,
Chart 4-36: The Use of Thoracic Aortic Aneurysm (TAA) Stent-Grafts, Global
Responses, 2010 69
Chart 4-37: Concerns about the Use of TAA Stent-Grafts, Global Responses,
2010 72
Chart 4-38: Most Promising Vulnerable Plaque Screening Technology, Global
Responses, 2010 76
Chart 4-39: Most Promising Vulnerable Plaque Treatment Technology, Global
Responses, 2010 79
U.S. STENTS, STENT-GRAFTS AND VULNERABLE PLAQUE. 80
Chart 5-1: Total Number of Stents Placed per Month, U.S. Responses, 2010. 84
Chart 5-2: Number of Coronary Stents Placed per Month, U.S. Responses,
2010 85
Chart 5-3: Number of Peripheral Stents Placed per Month, U.S. Responses,
2010 86
Chart 5-4: Type of Medical Imaging Used for Endovascular Procedures, U.S.
Responses, 2010 90
Chart 5-5: Bifurcated Stents and Their Use, U.S. Responses, 201 . 91
Chart 5-6: Most Important Benefit When Using Bifurcated Stents, U.S.
Responses, 2010 93
Chart 5-7: Drawbacks to the Use of Bifurcated Stents, U.S. Responses, 2010 . 96
Chart 5-8: Preferred Bifurcated Stent Alternatives, U.S. Responses, 2010 98
Chart 5-9: Preferred Bifurcated Stent Alternatives by Specialty, U.S. Responses,
2010 101
Chart 5-10: Bioabsorbable Stents and Their Use, U.S. Responses, 2010 102
Chart 5-11: Most Important Benefit When Using Bioabsorbable Stents, U.S.
Responses, 2010 104
Chart 5-12: Most Important Bioabsorbable Stent Drawback, U.S. Responses,
2010 106
Chart 5-13: Most Important Drug-Eluting Stent Concern, U.S. Responses, 2010108
Chart 5-15: Most Effective Drug-Eluting Stent Drug for Combating Restenosis
by Specialty, U.S. Responses, 2010 113
Chart 5-16: Preferred Brand of Stent-Graft, U.S. Responses, 2010 . 115
Chart 5-17: Most Important Construction Feature for Stent-Grafts, U.S.
Responses, 2010 117
Chart 5-18: Most Important Design Feature for Next-Generation Stent-Grafts,
Chart 5-19: Use of TAA Stent-Grafts, U.S. Responses, 2010 121
Chart 5-20: Concerns about the Use of TAA Stent-Grafts, U.S. Responses,
2010 123
Chart 5-21: Most Promising Vulnerable Plaque Screening Technology, U.S.
Responses, 2010 126
Chart 5-22: Most Promising Vulnerable Plaque Screening Technology by



Chart 5-23: Most Promising Vulnerable Plaque Treatment Technology, U.S.
Responses, 2010 132
Chart 5-24: Most Promising Vulnerable Plaque Treatment Technology by
Chart 6-1: Total Number of Stents Placed per Month, European Responses,
2010 140
Chart 6-2: Number of Coronary Stents Placed per Month, European Responses,
2010 141
Chart 6-3: Number of Peripheral Stents Placed per Month, European Responses,
2010 142
Chart 6-4: Type of Medical Imaging Used for Endovascular Procedures,
Chart 6-5: Bifurcated Stents and Their Use, European Responses, 2010 146
Chart 6-6: Most Important Benefit When Using Bifurcated Stents, European
Responses, 2010 148
Chart 6-7: Drawbacks to the Use of Bifurcated Stents, European Responses,
2010 150
Chart 6-8: Preferred Bifurcated Stent Alternatives, European Responses,
2010 152
Chart 6-9: Preferred Bifurcated Stent Alternatives by Specialty, European
Responses, 2010 154
Chart 6-10: Bioabsorbable Stents and Their Use, European Responses, 2010 155
Chart 6-11: Most Important Benefit When Using Bioabsorbable Stents,
Chart 6-12: Most Important Bioabsorbable Stent Drawback, European
Responses, 2010 159
Chart 6-13: Most Important Drug-Eluting Stent Concern, European Responses,
2010 161
Chart 6-15: Most Effective Drug-Eluting Stent Drug for Combating Restenosis
by Specialty, European Responses, 2010 166
Chart 6-16: Preferred Brand of Stent-Graft, European Responses, 2010 168
Chart 6-17: Most Important Construction Feature for Stent-Grafts, European
Responses, 2010 170
Chart 6-18: Most Impor


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.

Global Physician Survey on Stents, Stent-Grafts and Vulnerable Plaque Treatment 2011

Product Formats
Please select the product formats and the quantity you require.

Hard Copy--USD 10 995.00 Quantity: _____

1 User License--USD 11 495.00 Quantity: _____

Corporate License--USD 13 995.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


Global Physician Survey on Stents, Stent-Grafts and Vulnerable Plaque Treatment 2011

Recommended

Recommended

More Related Content

Similar to Global Physician Survey on Stents, Stent-Grafts and Vulnerable Plaque Treatment 2011

Similar to Global Physician Survey on Stents, Stent-Grafts and Vulnerable Plaque Treatment 2011 (20)

More from ReportLinker.com

More from ReportLinker.com (20)

Global Physician Survey on Stents, Stent-Grafts and Vulnerable Plaque Treatment 2011